Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quetiapine Treatment for Borderline Personality Disorder
NCT00122070Phase 3Completed
- Sponsor
- University of Medicine and Dentistry of New Jersey
- Start
- May 2005
- Primary completion
- Sep 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of quetiapine in borderline personality disorder (BPD), sponsored by University of Medicine and Dentistry of New Jersey. Primary endpoint: Symptom Checklist 90-Revised at 8 weeks. Started May 2005; status: completed.
02
Drugs
quetiapine
03
Conditions
borderline personality disorder (BPD)
Beyond the preview
Go deeper on NCT00122070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00122070.